New York, New York--(Newsfile Corp. - February 9, 2018) - NetworkNewsAudio announces the Audio Press Release (APR) titled
"Investment Opportunities in Advanced Bioengineered Drug Delivery," featuring PreveCeutical Medical Inc. (OTCQB: PRVCF) (CSE: PREV)
(FSE: 18H).
To hear the NetworkNewsAudio version, visit: LINK.
To read the original editorial, visit: LINK.
Not a one-trick-pony, PreveCeutical has already brought one product to market and is developing a diverse portfolio of
research and development programs that address large market diseases. PreveCeutical Medical's first commercial product, CELLB9®,
is an oral dilute solution infused with select peptides and proteins isolated from Caribbean Blue Scorpion venom. The active
ingredients in CELLB9 have been used around the world for over 25 years and have generated volumes of anecdotal reports about
their efficacy. PreveCeutical's research team is now using proprietary chemistry to generate Nature Identical™ peptides (http://nnw.fm/B9bBj) for a range of ailments. PreveCeutical and its Australian research
commercialization partner, UniQuest, are currently screening these peptides for use against some of the most aggressive diseases
where there exist unmet clinical needs.
In conjunction with leading Australian research centers, PreveCeutical is also pursuing dual-gene therapy research as both a
preventative measure and possible treatment for type 2 diabetes and obesity. Over five years of multi-disciplinary research has
generated convincing results in disease models that a single gene may be implicated in Type 2 diabetes and obesity.
PreveCeutical's gene-silencing technology would effectively turn off the genetic signal that leads to the over-production of a
key protein molecule, in turn reducing blood sugar levels and preventing the body from storing excessive fat. As Dr. Parekh
stated in a press release, "…gene-silencing does not represent a mere management for diabetes and obesity, it represents the
potential for a bona fide cure…"
In what may be a quantum leap in addressing the critical demand for non-addictive pain medications, PreveCeutical and its
partner UniQuest are expanding the use of their disulphide linker technology to develop non-addictive analgesics for
moderate-to-severe pain (http://nnw.fm/4TQgv). The four-phase research program
will be led by Dr. Parekh and carried out in collaboration with pain and inflammation pharmacology experts at the University of
Queensland.
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and
nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and
development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel
platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of
various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and
oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical
sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals
extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information visit www.PreveCeutical.com.
About NetworkNewsAudio
NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press
releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of
position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.
For more information, visit: www.NetworkNewsAudio.com
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire
services via NetworkWire to reach all target markets, industries and demographics in the most effective manner
possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum
impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of
corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW
is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers,
journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients
unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more
information, please visit https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever
published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof.
In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking statements.
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
